期刊
NATURE MEDICINE
卷 21, 期 10, 页码 1163-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3952
关键词
-
资金
- German Research Foundation [SFB824/C4]
- European Union [602783]
- German Cancer Consortium (DKTK)
- Lustgarten Foundation
- Tobacco-Related Disease Research Program
- Stanford University
- Child Health Research Institute
- Lucile Packard Foundation for Children's Health at Stanford
- Boehringer Ingelheim Fonds MD Fellowship
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors targeting chromatin regulators as possible therapeutic agents in PDAC. We show that JQ1, an inhibitor of the bromodomain and extraterminal (BET) family of proteins, suppresses PDAC development in mice by inhibiting both MYC activity and inflammatory signals. The histone deacetylase (HDAC) inhibitor SAHA synergizes with JQ1 to augment cell death and more potently suppress advanced PDAC. Finally, using a CRISPR-Cas9-based method for gene editing directly in the mouse adult pancreas, we show that de-repression of p57 (also known as KIP2 or CDKN1C) upon combined BET and HDAC inhibition is required for the induction of combination therapy-induced cell death in PDAC. SAHA is approved for human use, and molecules similar to JQ1 are being tested in clinical trials. Thus, these studies identify a promising epigenetic-based therapeutic strategy that may be rapidly implemented in fatal human tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据